A Randomized, Double-Blind, Placebo-controlled, Parallel, Exploratory Phase 2a Study to Evaluate Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
Latest Information Update: 10 Mar 2025
At a glance
- Drugs Emilimogene sigulactibac (Primary)
- Indications Diabetic foot ulcer; Wounds
- Focus Adverse reactions
- Sponsors Ilya Pharma
Most Recent Events
- 14 Jan 2025 According to ClinicalTrials.gov record, this trial is Terminated due to Patient recruitment issues
- 14 Jan 2025 Status changed from recruiting to discontinued.
- 20 Oct 2022 Status changed from planning to recruiting.